The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Upfront treatment of ROS1-rearranged NSCLC
Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, discusses how to choose the optimal therapy for the upfront treatment of ROS1-rearranged non-small cell lung cancer (NSCLC). Dr Cappuzzo outlines the potential benefits and limitations of crizotinib, entrectinib and lorlatinib for patients with ROS1-rearranged NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
